Install
- 373articles · 365d
- 2+ day agolatest article
- Jan 1, 2026earliest in window
- 54%with images
- 257avg words
- Medical 338
- Health & Wellness 329
- Health 274
- Education 40
- Science & Technology 19
- Disaster, Accident & Emergency Incident 15
- Human Interest 13
- Jobs & Education 13
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
FDA Grants DT120 Second Breakthrough Designation, Now for MDD
3+ day, 10+ hour ago (522+ words) The US FDA has granted Breakthrough Therapy designation to DT120, lysergide in the form of an oral disintegrating tablet (ODT) developed by Definium Therapeutics, for the treatment of MDD. The designation is supported by evidence of “significant unmet medical need” in the…...
Zanidatamab-Based Regimens Redefine First-Line Treatment of HER2-Positive Gastroesophageal Adenocarcinoma
4+ day, 12+ hour ago (652+ words) Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, New York, discusses how findings from the phase 3 HERIZON-GEA-01 trial are reshaping first-line treatment of HER2-positive gastroesophageal adenocarcinoma following the approval of zanidatamab plus chemotherapy, with or without tislelizumab. He…...
FDA Approves Camizestrant Plus CDK4/6 Inhibitor Following Emergence of ESR1 Mutation in Advanced Breast Cancer
4+ day, 14+ hour ago (273+ words) Based on results from the phase 3 SERENA-6 trial, the US Food and Drug Administration (FDA) granted accelerated approval to camizestrant (Etcamah; AstraZeneca) in combination with a CDK4/6 inhibitor for patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer following detection…...
FDA Approves Zanidatamab-Based Regimens for First-Line HER2-Positive Advanced Gastroesophageal Adenocarcinoma
2+ week, 4+ day ago (192+ words) The approval of zanidatamab plus tislelizumab and chemotherapy applies to patients with HER2 IHC 3+ or IHC 2+/ISH+ tumors, while zanidatamab plus chemotherapy without tislelizumab is approved for patients with HER2 IHC 3+ disease. HER2 positivity must be confirmed using an FDA-approved test. PFS was…...
Clinical Perspectives Through an Integrated Triple Monoamine Lens
3+ week, 3+ day ago (21+ words) HMP Global Learning Network - Transforming ADHD Care: Viloxazine ER vs Atomoxetine Roundtable Discussion...
Challenges and Considerations With Clinical Evaluation of Associated Features
3+ week, 3+ day ago (503+ words) HMP Global Learning Network Some of the data collected by this provider is for the purposes of personalization and measuring advertising effectiveness. The provider may use the IP Addresses for ads measurement and ads personalization. - h415.hmpgloballearningnetwork.com 2 AWSALB [x2]Registers which…...
Early Detection and Timely Reintervention Drive Success After Deep Venous Arterialization
1+ mon, 5+ day ago (355+ words) HMP Global Learning Network Early Detection and Timely Reintervention Drive Success After Deep Venous Arterialization On Friday morning at the Amputation Prevention Symposium, Yana Etkin, MD, presented an in-depth review of strategies for identifying and managing failing deep venous arterialization…...
Defining Optimal Medical Therapy for CLTI in 2026
1+ mon, 5+ day ago (552+ words) HMP Global Learning Network Defining Optimal Medical Therapy for CLTI in 2026 On Friday morning at the Amputation Prevention Symposium, Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM, presented a review of the evidence supporting contemporary medical management for patients…...
Behind the Bubbles: A Guide to Surfactants as Potential Allergens
1+ mon, 1+ week ago (14+ words) HMP Global Learning Network...
Access to Atrial Flow Regulators for Implantation in Critically Ill Children Via the US Food and Drug Administration’s Emergency Use Pathway
1+ mon, 2+ week ago (616+ words) J INVASIVE CARDIOL 2026. doi:10.25270/jic/26.00133. Epub July 28, 2026. Objectives. The authors conducted a review of the US Food and Drug Administration’s (FDA) emergency use authorization (EUA) pathway as a mechanism to use the Occlutech Atrial Flow Regulator (AFR) (Occlutech International AB)…...